←Adolescence & Development
Study register · detail Bevölkerungsbasierte Querschnittsstudie · Adolescence & Development · 2008

Association of cannabis use with prodromal symptoms of psychosis in adolescence.

Miettunen et al. ·The British Journal of Psychiatry
Harm GRADE High 85 citations
Samplen = 6.330 Pat.
ControlNo cannabis use
EndpointProdromal symptoms of…
Blindingn.a.
DesignBevölkerungsbasierte Querschnittsstudie
Key finding

Cannabis use is associated with significantly increased prodromal psychosis symptoms in adolescents.

Summary

Population-based study (n=6.330 adolescents, 15–16 years); cannabis use (n=352; 5,6%) associated with ≥3 prodromal psychosis symptoms (OR=2,23; 95%-CI 1,70–2,94), also after adjustment for covariates including prior behavioural symptoms; dose-response effect demonstrated.

P
PopulationAdolescents aged 15–16 years, n=6330, population-based cross-sectional study
I
InterventionCannabis use (ever tried, n=352, 5,6%)
C
ControlNo cannabis use
O
OutcomeSignificantly increased probability of ≥3 prodromal psychosis symptoms in cannabis users (OR=2,23; 95% CI 1,70–2,94), also after adjustment for confounders; dose-response relationship observed
Confidence in the evidence
High

The highest of four GRADE levels, the effect estimate is very reliable.

Quality profile
Sample size ★★★★★
Blinding —
Effect size Harm
Citations / year ★★★★★
Authors
Miettunen J, Törmänen S, Murray GK, Jones PB, Mäki P, Ebeling H, Moilanen I, Taanila A, Heinimaa M, Joukamaa M, Veijola J.
DOI 10.1192/bjp.bp.107.045740↗
Design: Bevölkerungsbasierte Querschnittsstudie
Share
Abstract
Recent interest has focused on the association between cannabis use and risk of psychosis. In the largest unselected, population-based study on this topic to date, we examined cannabis use and prodromal symptoms of psychosis at age 15-16 years among 6330 adolescents. Those who had tried cannabis (n=352; 5.6% of the total sample) were more likely to present three or more prodromal symptoms even after controlling for confounders including previous behavioural symptoms (OR=2.23; 95% CI 1.70-2.94). A dose-response effect was seen. We conclude that cannabis use is associated with prodromal symptoms of psychosis in adolescence.
Indication
Further studies on Adolescence & Development
All studies →
S Gobbi et al. · 2019 · JAMA Psychiatry
886 citations
Association of Cannabis Use in Adolescence and Risk of Depression, Anxiety, and Suicidality in Young Adulthood
Clear benefit Meta-Analyse

SR über 11 Studien (n=23.317 Jugendliche); adoleszenter Cannabis-Konsum assoziiert mit erhöhtem Risiko für Depression im jungen Erwachsenenalter (OR=1.37, 95% CI 1.16-1.62, p0.001), Angststörungen (OR=1.18, 95% CI 1.10-1.26, p0.001) und Suizidalität (OR=1.50, 95% CI 1.11-2.03, p0.01).

10.1001/jamapsychiatry.2018.4500 View study →
S Silins et al. · 2014 · The Lancet Psychiatry
438 citations
Young adult sequelae of adolescent cannabis use: an integrative analysis.
Harm IPD-Meta-Analyse (3 Longitudinalstudien)

IPD-Meta-Analyse (N bis 3.765); täglicher Cannabiskonsum vor 17 Jahren: aOR 0,37 (CI 0,20–0,66) für Schulabschluss, 17,95 (CI 9,44–34,12) für Cannabisabhängigkeit, 7,80 (CI 4,46–13,63) für andere illegale Drogen, 6,83 (CI 2,04–22,90) für Suizidversuch; klare Dosis-Wirkung für alle 7 Entwicklungs-Outcomes.

10.1016/s2215-0366(14)70307-4 View study →
S Andréasson et al. · 1987 · The Lancet
1144 citations
Cannabis and schizophrenia. A longitudinal study of Swedish conscripts.
Harm Prospektive Kohortenstudie

Prospektive 15-Jahres-Kohortenstudie (n=45.570 schwedische Wehrpflichtige); Hochkonsumenten (>50 Gelegenheiten) hatten RR=6,0 (95%-KI 4,0–8,9) für Schizophrenie vs. Nicht-Konsumenten; Cannabis als unabhängiger Risikofaktor nach Adjustierung für andere psychiatrische Erkrankungen und sozialen Hintergrund bestätigt.

10.1016/s0140-6736(87)92620-1 View study →

The impediment to action advances action. — Marcus Aurelius